Effects of Nanoliposomal and Pegylated Nanoliposomal Artemisinin in Treatment of Breast Cancer
- 1 October 2013
- journal article
- research article
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 29 (4) , 501-504
Abstract
This study is aimed to investigate the nanoliposomal artemisinin preparation, and its implementation on breast cancer cells. Side effects have been one of the common challenges of drug usage, as well as cancer treatment. In order to reduce such effects, nanotechnology has been a great help. Nanoliposomes are provided through reverse phase evaporation. In this method, certain proportions of phosphatidylcholine, cholesterol and artemisinin were mixed together. Besides, the obtained formulation was pegylated by using polyethylene glycol 2000 in order to increase its stability and solubility. The mean diameter of non-pegylated and pegylated liposomal artemisinin was determined by Zeta sizer system. The percent of drug released from liposome was performed by dialysis. The encapsulation efficiency of both formulations was estimated by spectrophotometry method. As a result, encapsulation and drug release of nanoliposomal formulation were more than the pegylation of the same formulation. In addition, this study indicated that cytotoxicity effect of pegylated nanoliposomal artemisinin was more, in comparison with nanoliposomal artemisinin.Keywords
This publication has 16 references indexed in Scilit:
- Development of artemisinin compounds for cancer treatmentInvestigational New Drugs, 2012
- Liposome Technology for Industrial PurposesJournal of Drug Delivery, 2010
- The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophiliaInternational Journal of Nanomedicine, 2010
- Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cellsBioorganic & Medicinal Chemistry, 2009
- Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivoAnti-Cancer Drugs, 2009
- Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugationInternational Journal of Pharmaceutics, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Experimental study of environmental tobacco smoke particles under actual indoor environmentScience of The Total Environment, 2006
- Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the ratCancer Letters, 2006
- Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stabilityInternational Journal of Pharmaceutics, 2004